Continued Benefits of Zenocutuzumab Treatment in NRG1+ NSCLC Patients: Insights from the eNRGy Trial The eNRGy trial reveals promising results for zenocutuzumab as a treatment beyond progression in NRG1+ NSCLC patients, showing potential long-term benefits.

Continued Benefits of Zenocutuzumab Treatment in NRG1+ NSCLC Patients: Insights from the eNRGy Trial #United_States #Lexington #NSCLC #Zenocutuzumab #NRG1_Fusion

FDA Grants Orphan Drug Designation to Zenocutuzumab-zbco for Cholangiocarcinoma Treatment Partner Therapeutics announces FDA's Orphan Drug Designation for zenocutuzumab-zbco, targeting cholangiocarcinoma with NRG1 gene fusion. A hopeful advancement in rare cancer treatment.

FDA Grants Orphan Drug Designation to Zenocutuzumab-zbco for Cholangiocarcinoma Treatment #United_States #Lexington #Zenocutuzumab #Partner_Therapeutics #Cholangiocarcinoma

Significant Benefits of Zenocutuzumab in Treatment-Resistant Pancreatic and Cholangiocarcinoma Patients Recent findings from the eNRGy trial suggest that continuing zenocutuzumab treatment after disease progression can greatly benefit patients with NRG1+ pancreatic cancer and cholangiocarcinoma.

Significant Benefits of Zenocutuzumab in Treatment-Resistant Pancreatic and Cholangiocarcinoma Patients #United_States #San_Francisco #Cancer_Treatment #Zenocutuzumab #NRG1

FDA Grants Breakthrough Therapy Status to Zenocutuzumab-zbco for Challenging Cholangiocarcinoma Treatment The FDA has assigned a Breakthrough Therapy designation to zenocutuzumab-zbco aimed at treating NRG1-positive cholangiocarcinoma, highlighting promising interim trial results.

FDA Grants Breakthrough Therapy Status to Zenocutuzumab-zbco for Challenging Cholangiocarcinoma Treatment #USA #Lexington #Zenocutuzumab #Cholangiocarcinoma #NRG1

2. Zenocutuzumab: This FDA-approved therapy targets NRG1+ cancers, showing a 33% response rate in lung cancer and 40% in pancreatic cancer. Precision medicine at its finest! #Zenocutuzumab #LungCancer

Zenocutuzumab: A Novel Bispecific Antibody for NRG1 Fusion-Positive Pancreatic and Lung Cancers On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to zenocutuzumab (Bizengri®), the first approved systemic therapy for patients with advanced, unresectable, or m...

Just published in @nejm.org: In a clinical trial led by MSK's Dr. Alison Schram, #zenocutuzumab, a novel bispecific antibody, demonstrated durable antitumor activity and met prespecified goals for outstanding activity. bit.ly/4gvvvMA

#pancreaticcancer

New Research on Zenocutuzumab-zbco Marks a Breakthrough in NRG1+ Cancer Treatment A landmark study published in NEJM reveals the effectiveness of Zenocutuzumab-zbco (BIZENGRI®) for treating NRG1+ cancers, offering new hope to patients.

New Research on Zenocutuzumab-zbco Marks a Breakthrough in NRG1+ Cancer Treatment #USA #Lexington #NEJM #BIZENGRI #Zenocutuzumab

FDA approval: Zenocutuzumab for NRG1+ NSCLC - IASLC - OncoDaily FDA approval: Zenocutuzumab for NRG1+ NSCLC - IASLC / Alison Schram, cancer, FDA, ICYMI, Lung cancer, NRG1 fusion, NSCLC, OncoDaily, Oncology, Stephen V Liu,

FDA approval: Zenocutuzumab for NRG1+ NSCLC – IASLC

oncodaily.com/drugs/zenocu...

#ICYMI #Cancer #FDA #LungCancer #NRG1Fusion #NSCLC #OncoDaily #Oncology #Zenocutuzumab #Health #Medicine

2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA

1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib

#lcsm #OncSky #MedSky #Cancer

NEW 🚨: The @fda.gov has granted accelerated approval to #zenocutuzumab for treating patients with advanced #pancreaticcancer or non-small cell #lungcancer that has an alteration called an #NRG1 gene fusion and whose disease progressed after other treatments.

FDA grants accelerated approval to zenocutuzumab-zbco On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma.

The HER2:HER3 bispecific Ab #zenocutuzumab was #FDAapproved for advanced, unresectable, or metastatic NRG1 fusion+ NSCLC (ORR 33%; mDOR 7.4 mo) and NRG1 fusion+ pancreatic adenocarcinoma (ORR 40%; DOR 3.7-16.6 mo) after 1 systemic Tx #lcsm #pancan #oncsky #cansky #pansm bit.ly/41lRFwW @fda.gov

FDA grants accelerated approval to zenocutuzumab-zbco On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma.

#FDA grants accelerated approval to HER2/HER3 bispecific ab
#zenocutuzumab for previously treated advanced #NSCLC and #pancreatic cancer and #NRG1 fusion. Thanks to patients, PIs (Ali Schram, Alex Drilon, Jordi Rodon, Eileen O'Reilly, and others) #OncSky #MedSky
www.fda.gov/drugs/resour...